Berberine Protects Kidneys in Diabetes by Blocking Iron-Dependent Cell Death

Diabetic kidney disease affects 30-40% of diabetes patients and represents the leading cause of chronic kidney disease globally. Current treatments remain limited, creating urgent need for effective preventive strategies.

This comprehensive study examined berberine's protective mechanisms using both diabetic rat models and human kidney cell cultures. Researchers induced diabetes through high-fat diet combined with streptozotocin injection, then treated animals with berberine (200 mg/kg daily) for 16 weeks. In parallel cell studies, they exposed human kidney cells to advanced glycation end products (AGEs)—toxic compounds that accumulate in diabetes.

Berberine treatment dramatically improved kidney function markers including serum creatinine and blood urea levels. Histological analysis revealed reduced inflammatory cell infiltration, less podocyte damage, and decreased iron accumulation in kidney tissues. The compound also enhanced antioxidant enzyme activity and reduced oxidative stress markers. Importantly, berberine prevented ferroptosis—a recently discovered form of cell death driven by iron accumulation and lipid peroxidation.

Molecular investigations revealed berberine's mechanism: direct binding to Nuclear factor erythroid 2-related factor 2 (Nrf2), a master regulator of cellular antioxidant responses. Surface plasmon resonance confirmed strong binding affinity between berberine and Nrf2 protein. This interaction activated downstream protective genes including heme oxygenase-1 and glutathione peroxidase 4, which combat oxidative damage and prevent ferroptosis.

Crucially, when researchers silenced Nrf2 using genetic techniques, berberine completely lost its protective effects, proving this pathway's essential role. These findings provide the first evidence that berberine's kidney-protective effects operate through Nrf2-mediated ferroptosis inhibition, offering new therapeutic targets for diabetic complications.